We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| KraneShares Artificial Intelligence ETF | NASDAQ:AGIX | NASDAQ | Exchange Traded Fund |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 24.055 | 23.60 | 30.00 | 1 | 13:04:43 |
From Jul 2019 to Jul 2024
ATLANTA, GA , we are advised by the company that the time of the webcast in paragraph one should read "11:10 a.m. EDT" rather than "11:20 a.m. EDT" as originally issued. Complete corrected text follows.
AtheroGenics to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008
ATLANTA, GA -- April 30, 2008 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced its participation in the 2008 Morgan Stanley Global Healthcare Unplugged Conference on Friday, May 2, 2008 at 11:10 a.m. EDT.
The conference will feature its "Unplugged" presentation format with Morgan Stanley analysts hosting company management in an informal and interactive discussion with the investment community.
A live webcast of the Company's presentation may be accessed from 'Investor Relations' on the Company's website at www.atherogenics.com. The replay of the webcast will also be available on the Company's website for two weeks following the presentation. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead antioxidant and anti-inflammatory drug candidate, AGI-1067, is being studied in a Phase III clinical trial known as ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study), for the treatment of diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit http://www.atherogenics.com.
CONTACTS: AtheroGenics, Inc. Donna Glasky Corporate Communications 678-336-2517 Email Contact Media Inquiries Jayme Maniatis / Dana Conti Schwartz Communications, Inc. 781-684-0770 Email Contact Investor Inquiries Lilian Stern Stern Investor Relations, Inc. 212-362-1200 Email Contact
1 Year KraneShares Artificial I... Chart |
1 Month KraneShares Artificial I... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
